Modulation of luteinizing hormone subunit gene expression by intracerebroventricular microinjection of gonadotropin-releasing hormone or beta-endorphin in female rats.
The effects of gonadotropin-releasing hormone (GnRH), beta-endorphin and its antagonist naloxone on the expression of luteinizing hormone (LH) subunit genes and LH secretion were examined in ovariectomized and/or cycling female rats through their direct microinjection into the third cerebral ventricle, in the proximity of the hypothalamus-pituitary complex. GnRH (1 nM) induced a significant augmentation of the pituitary content of alpha mRNA when administered 15, 30 or 60 min intervals over 5 h to ovariectomized rats whereas only the 30 and 60 min intervals were effective in increasing LHbeta mRNA, and the 60 min intervals for LH release. This was in agreement with the established concept of a pulse-dependent regulation of gonadotropin synthesis and release. Hourly pulses of GnRH also increased alpha and LHbeta mRNA levels when microinjected in female cycling rats during proestrus or diestrus II. Using this model we observed a marked negative influence of hourly intracerebral microinjections of beta-endorphin on LH mRNA content and LH release in ovariectomized rats while naloxone had no effect. This suggests that endogenous beta-endorphin was unable to exert its negative action on beta-endorphin receptors that were present and responded to the ligand. The present approach would be valuable for the exploration of the mechanisms of action of beta-endorphin or other substances on the functions of the gonadotrophs.
Gajewska
A
A
Kielanowski Institute of Animal Physiology and Nutrition, Jablonna near Warsaw, Poland.
Kochman
K
K
Lerrant
Y
Y
Kochman
H
H
Counis
R
R
D000818:Animals; D002552:Cerebral Ventricles / Q000187:drug effects / Q000502:physiology*; D004971:Estrus; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D015292:Glycoprotein Hormones, alpha Subunit / Q000235:genetics* / Q000378:metabolism; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D007276:Injections, Intraventricular; D007986:Luteinizing Hormone / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D008845:Microinjections; D009270:Naloxone / Q000008:administration & dosage / Q000494:pharmacology; D010052:Ovariectomy; D010903:Pituitary Gland, Anterior / Q000187:drug effects / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D001615:beta-Endorphin / Q000008:administration & dosage / Q000494:pharmacology*
D015292:Glycoprotein Hormones, alpha Subunit; D007987:Gonadotropin-Releasing Hormone; D009270:Naloxone; D001615:beta-Endorphin; D007986:Luteinizing Hormone